Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The hitherto lesser-known Google subsidiary aims to revolutionize drug development by using advanced AI to create medicines more quickly, affordably, and accurately than traditional methods.

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a significant leap in pharmaceutical innovation.

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in fields like cancer and immunology using artificial intelligence.